ArticlePulmonary medicine2026
Untargeted and Targeted Liquid Chromatography-Mass Spectrometry-Based Lipidomic Profiling Revealed a Potential Biomarker Panel to Distinguish Clinical Isolates of M. tuberculosis From Nontuberculous M. kansasii.
Article in Pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The rising incidence of nontuberculous mycobacteria (NTM) infections, particularly Mycobacterium kansasii (M. kansasii), and their overlapping clinical features with Mycobacterium tuberculosis (MTB) are leading to diagnostic ambiguity in tuberculosis-endemic regions. Accurate differentiation remains limited by conventional diagnostic methods, emphasizing the need for molecular- and lipid-based biomarkers. In the present era of "OMICS" sciences, herein we attempted a comprehensive analysis of MTB and M. kansasii lipid profiles to elucidate species-specific lipidomic features as potential biomarkers. Three clinical isolates each of MTB and M. kansasii were obtained from treatment-naïve patients with microbiologically confirmed pulmonary infections. Lipid profiling was performed by integrating untargeted and targeted profiling through ultraperformance liquid chromatography coupled with tandem mass spectrometry from bacilli total lipid and mycobacterial cell wall lipid extracts. Untargeted profiling exhibited a higher abundance of fatty acyls, GLs, selected GPLs (PE, PG, PI, and PA), and saccharolipids (SLs) specifically Ac2SGL in MTB, whereas M. kansasii isolates were characterized by elevated levels of GPLs like PC and LPC, polyketides, and specific SLs such as diacylated trehalose species. Targeted quantification confirmed differential expression of GL (TG and DG) and GPL (PC, PE, LPC, PI, and PS) species, supporting their diagnostic relevance. Additionally, biomarker analysis further identified five lipid species with strong discriminative potential. Collectively, these findings support the development of a robust lipidomic biomarker panel for the accurate differentiation of MTB and M. kansasii, with potential implications for improved diagnostics and targeted therapeutic strategies after further confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.